Thoughts about this paper?

[Faaska]

Serum IGF-I is not a reliable pharmacodynamic marker of exogenous growth hormone activity in mice - PubMed

Serum IGF-I is a well-established pharmacodynamic marker of GH administration in humans and has been used for this purpose in animal studies. However, its general suitability in wild-type laboratory mice has not been demonstrated. Here we show that treatment with recombinant human GH (rhGH) in...

pubmed.ncbi.nlm.nih.gov

Tldr:
Increase in mass and muscle were observed in mice treated by hgh,while serum igf1 levels didn't increase (probably due to somatosin inhibition of igf1 production). Is the fat loss/energy releasing component of hgh important for increases in mass? This would also explain subpar results for igf 1 therapy.

P.s this dosent apply as much to humans although we do have somatosin levels rise I've seen a lot of studies in which igf 1 levels have risen during therapy

Responses to growth hormone (GH) therapy in short children with normal GH secretion and no bone age delay: an analysis of potential factors affecting their response to rhGH therapy. A controlled study - PubMed

We report significant gain in Ht-SDS in prepubertal children with ISS on rhGH therapy and better response in younger children and in those with Ht-SDS > 1 SD below their MP-Ht-SDS.

pubmed.ncbi.nlm.nih.gov

This study leads me to believe a stack for heightmaxxing should be all encompassing for maximum results. E.g AI,Somatosin inhibitor,hgh and/or without igf 1 (preferably not L3 due to it not binding to binding proteins) and something to manage insulin issues like test or metformin.

 

[Maalik]

Cool we need biochemistry degrees to gain 2 inches

 

[Faaska]

Cool we need biochemistry degrees to gain 2 inches

Blast and cruise my friend

 

[LVZZO]

That's is a heightmaxxing stack jfl
mk677 does this too but don't tell the 12yo kids here
It works but at health cost (maybe), can be permanent (or not)
Who knows

Spoiler

The effect of 2 months of treatment with the oral growth hormone (GH) secretagogue MK-677 on markers of bone metabolism was determined in healthy obese male subjects. This was a randomized, double-blind, parallel, placebo-controlled study. Twenty-four healthy obese males, 19-49 years of age, with body mass index > 30 kg/m2 were treated with MK-677 (25 mg/day; n = 12) or placebo (n = 12) for 8 weeks. MK-677 increased markers of bone formation; a 23% increase in the carboxy-terminal propeptide of type I procollagen levels and a 28% increase in procollagen III peptide levels were seen with as little as 2 weeks of MK-677 treatment (p < 0.01 and p = 0.001 vs. placebo, respectively) while a 15% increase in serum levels of osteocalcin was not detected until 8 weeks of treatment (p < 0.01 vs. placebo). Markers of bone resorption were induced within 2 weeks of treatment with MK-677; serum levels of the carboxy-terminal cross-linked telopeptide of type I collagen were increased 26% at 8 weeks (p = 0.001 vs. placebo), and urine hydroxyproline/creatinine and calcium/creatinine ratios at 8 weeks were increased by 23% (p < 0.05 vs. placebo) and 46% (p < 0.05 vs placebo), respectively, MK-677 increased serum insulin-like growth factor binding protein-5 (IGFBP-5) by 43-44% after 2-8 weeks of treatment (p < 0.01 vs. placebo). Serum IGFBP-4 was increased by 25% after 2 weeks of treatment (p < 0.001 vs. placebo) but no significant change from baseline was observed after 8 weeks of treatment. Plasma interleukin-6 was not significantly changed by active treatment. In conclusion, short-term treatment of healthy obese male volunteers with the GH secretagogue MK-677 increases markers of both bone resorption and formation. Large increases in serum levels of IGF-1 and IGFBP-5 and a transient increase in serum IGFBP-4 were found. Future long-term studies are needed to investigate if prolonged treatment with MK-677 increases bone mass.

Treatment with the oral growth hormone secretagogue MK-677 increases markers of bone formation and bone resorption in obese young males - PubMed

The effect of 2 months of treatment with the oral growth hormone (GH) secretagogue MK-677 on markers of bone metabolism was determined in healthy obese male subjects. This was a randomized, double-blind, parallel, placebo-controlled study. Twenty-four healthy obese males, 19-49 years of age...

pubmed.ncbi.nlm.nih.gov

 

[Faaska]

That's is a heightmaxxing stack jfl
mk677 does this too but don't tell the 12yo kids here
It works but at health cost (maybe), can be permanent (or not)
Who knows

Spoiler

The effect of 2 months of treatment with the oral growth hormone (GH) secretagogue MK-677 on markers of bone metabolism was determined in healthy obese male subjects. This was a randomized, double-blind, parallel, placebo-controlled study. Twenty-four healthy obese males, 19-49 years of age, with body mass index > 30 kg/m2 were treated with MK-677 (25 mg/day; n = 12) or placebo (n = 12) for 8 weeks. MK-677 increased markers of bone formation; a 23% increase in the carboxy-terminal propeptide of type I procollagen levels and a 28% increase in procollagen III peptide levels were seen with as little as 2 weeks of MK-677 treatment (p < 0.01 and p = 0.001 vs. placebo, respectively) while a 15% increase in serum levels of osteocalcin was not detected until 8 weeks of treatment (p < 0.01 vs. placebo). Markers of bone resorption were induced within 2 weeks of treatment with MK-677; serum levels of the carboxy-terminal cross-linked telopeptide of type I collagen were increased 26% at 8 weeks (p = 0.001 vs. placebo), and urine hydroxyproline/creatinine and calcium/creatinine ratios at 8 weeks were increased by 23% (p < 0.05 vs. placebo) and 46% (p < 0.05 vs placebo), respectively, MK-677 increased serum insulin-like growth factor binding protein-5 (IGFBP-5) by 43-44% after 2-8 weeks of treatment (p < 0.01 vs. placebo). Serum IGFBP-4 was increased by 25% after 2 weeks of treatment (p < 0.001 vs. placebo) but no significant change from baseline was observed after 8 weeks of treatment. Plasma interleukin-6 was not significantly changed by active treatment. In conclusion, short-term treatment of healthy obese male volunteers with the GH secretagogue MK-677 increases markers of both bone resorption and formation. Large increases in serum levels of IGF-1 and IGFBP-5 and a transient increase in serum IGFBP-4 were found. Future long-term studies are needed to investigate if prolonged treatment with MK-677 increases bone mass.

Treatment with the oral growth hormone secretagogue MK-677 increases markers of bone formation and bone resorption in obese young males - PubMed

The effect of 2 months of treatment with the oral growth hormone (GH) secretagogue MK-677 on markers of bone metabolism was determined in healthy obese male subjects. This was a randomized, double-blind, parallel, placebo-controlled study. Twenty-four healthy obese males, 19-49 years of age...

pubmed.ncbi.nlm.nih.gov

A Stack of just ghrelin would definitely cause long term issues. Gherline stimulates hgh production which stimulates energy to be released (raising bg) and also producing igf 1 which as it is similar to insulin would bind to the same things. Long term high amounts of insulin numbs the body to insulin (insulin reistance) which causes type 2 diabetes jfl.

 

[LVZZO]

Long term high amounts of insulin numbs the body to insulin (insulin reistance) which causes type 2 diabetes jfl.

Don't know about causing diabetes, maybe it can happen, but yes it's true that fucks your sugar and insulin levels